MARKET

QNRX

QNRX

Quoin Pharmaceuticals Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6299
-0.0202
-3.11%
After Hours: 0.6300 +0.0001 +0.02% 19:58 05/20 EDT
OPEN
0.6600
PREV CLOSE
0.6501
HIGH
0.6773
LOW
0.6100
VOLUME
46.19K
TURNOVER
0
52 WEEK HIGH
35.52
52 WEEK LOW
0.5500
MARKET CAP
5.28M
P/E (TTM)
-0.0520
1D
5D
1M
3M
1Y
5Y
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Decisionpoint Systems, Inc. (NASDAQ: DPSI) rose 47.2% to $7.02 in pre-market trading after jumping around 19% on Tuesday. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million.
Benzinga · 3d ago
Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome
Quoin Pharmaceuticals (QNRX) is developing a potential treatment for a patient population in desperate need. We spoke with CEO, Dr. Michael Myers, to find out more about Netherton Syndrome, a rare and devastating genetic disease. New York, New York--(Newsf...
Newsfile · 4d ago
When Will Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Breakeven?
Quoin Pharmaceuticals, Ltd. ( NASDAQ:QNRX ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 05/11 15:24
--Ladenburg Thalmann Starts Quoin Pharmaceuticals at Buy With $2 Price Target
MT Newswires · 05/06 07:32
QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT
Benzinga · 04/30 17:41
Why Quoin Pharmaceuticals Stock Is Trading Higher
Quoin Pharmaceuticals (NASDAQ: QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigational New Drug application for QRX003.
Benzinga · 04/25 15:29
Nkarta, ERYTECH Pharma top healthcare gainers; Eliem, Clarus lead losers' pack
Gainers: Nkarta NKTX +84%. ERYTECH Pharma ERYP +54%. Sunshine Biopharma (SBFM) +25%. Rubius Therapeutics RUBY +17%. Quoin Pharmaceuticals QNRX +12%. Losers: Eliem Therapeutics ELYM -55%. Clarus Therapeutics Holdings CRXT -54%.  Axsome Therapeutics AXSM -20...
Seekingalpha · 04/25 14:04
Quoin soars on FDA clearance to start testing of its QRX003 lotion for rare skin disorder
American depositary shares of Quoin Pharmaceuticals (NASDAQ:QNRX) have added 45.7% in premarket trading on Monday after the U.S. Food and Drug Administration cleared the company's new drug application for its
Seekingalpha · 04/25 13:04
More
No Data
Learn about the latest financial forecast of QNRX. Analyze the recent business situations of Quoin Pharmaceuticals Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average QNRX stock price target is 4.913 with a high estimate of 8.00 and a low estimate of 2.000.
High8.00
Average4.913
Low2.000
Current 0.6299
EPS
Actual
Estimate
-3.90-2.93-1.95-0.98
Q4 2018
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Institutional Holdings
Institutions: 15
Institutional Holdings: 547.43K
% Owned: 6.53%
Shares Outstanding: 8.39M
TypeInstitutionsShares
Increased
0
0
New
4
94.16K
Decreased
1
32.99K
Sold Out
5
127.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Abraham Nahmias
Chief Executive Officer/Director
Shai Yarkoni
Chief Financial Officer
Eyal Leibovitz
Chief Operating Officer/Vice President
Amos Ofer
Vice President - Research & Development
Amotz Nehushtan
Other
Guy Sapir
Independent Director
Ronit Biran
Independent Director
David Braun
Independent Director
Jonathan Burgin
Independent Director
Yali Sheffi
No Data
No Data
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Webull offers kinds of Quoin Pharmaceuticals Ltd - ADR stock information, including NASDAQ:QNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QNRX stock methods without spending real money on the virtual paper trading platform.